HQ
Columbus, Ohio
Founded
2016
Founders and CEO
Robert Shalwitz, Founder and CEO
Sector
Life Sciences

Company Profile

Invirsa's lead compound, INV-102, is derived from a naturally occurring molecule that combats viral conjunctivitis (viral pinkeye) by enhancing the body's own ability to fight the disease.

Blogs About Invirsa

Invirsa Secures Seed Financing to Develop New Approach to Treating Common Infectious Diseases that Affect Millions Annually
Invirsa Develops Natural Compound to Treat Pinkeye

Invirsa in the News

Invirsa is Developing a Drug for Viral Infection Treatment
CincyInno
Invirsa Takes Aim at Pinkeye Treatment
Wall Street Journal WSJ
Drug developer Invirsa snags $520K
PE HUb
Invirsa Secures $520K in Seed Funding
Finsmes